Browsing articles by " Lynkeus"

How CARDIOPROOF helps in the decision making process: a Concrete Clinical Scenario


At the German heart institute in Berlin, clinicians face many situations in clinical everyday practice in which the decision-making process is not always straightforward. This is the case of a six years old boy, who we had in cure, with a combined disease of bicuspid aortic valve and coarctation of the aorta. He came to us after having undergone already two balloon angioplasties in the past. He wasn’t taking medication and presented arterial hypertension. When measuring his blood pressure around both arms and both legs we found a gradient of 11mmHg, and by ECG examination we found a gradient of 43 mmHg: these are very high values compared to normal blood pressure values In the MRI scans we detected that there were two situations wherethe narrowing of the aorta took place.That circumstance put us in front of two choices: place a stent or not in these two locations? Where to exactly place it?

Read more..

Transcatheter interventions for aortic coarctation

Taking a closer look atthe existing evidence

Accounting for 5-8% of all congenital heart defects, coarctation of the aorta is associated with increased morbidity and mortality even years after treatment. Percutaneous catheter interventions are attractive treatment alternatives to surgical repair in patients with suitable anatomy and include balloon dilatation and stenting. As part of the FP7-funded CARDIOPROOF project, researchers Maximilian Salcher and Huseyin Naci of the London School of Economics and Political Science (LSE) led a recent systematic review and meta-analysis of clinical studies to assess whether one of these intervention strategies leads to better results. Both researchers are based at LSE Health, one of the largest research centres of the LSE.

Read more..

Fluid-structure interaction modelling for assessing dilatation of ascending aorta

Within CARDIOPROOF Siemens is interested in validating coupled computational models of blood flow and wall deformation for assessing the role of haemodynamics, wall mechanics and anatomy in dilatation of ascending aorta. Aortic arch dilatation occurs frequently and at a young age in patients with aortic disease, such as aortic valve disease (AVD) and aortic coarctation (CoA) specifically addressed in the project. Moreover, independently of the type of aortic disease, aortic dilation is a significant predictor of dissection and rupture (acute cardiovascular events leading to death if untreated), thus evolution of aortic arch dilation is important for prognostics.

Read more…

Haemodynamical modelling of the ventricle and aortic valve

[read more…]

Background and motivation
CARDIOPROOF focuses on patients with aortic valve disease (AVD) and coarctation of the aorta (CoA), disorders that are characterized by LV pressure and/or volume overload. Such overload induces a complex cascade of myocardial and vascular wall remodelling (eccentric/concentric hypertrophy, myocardial fibrosis, etc.), which if left untreated can progress to heart failure. In severe cases of AVD and CoA, treatment is necessary, however the optimum timing and the best type of treatment are difficult to determine. Guidelines of the European Society of Cardiology (ESC) and Association for Paediatric and Congenital Cardiology (AEPC) are complex and rely mostly on gross parameters from echocardiographic measurements (global ventricular pump function), arterial blood pressures and clinical symptoms.
A potentially powerful approach to improve diagnosis, patient selection and therapy delivery is the use of patient-specific computational models, which are built using data routinely recorded in the clinic.


The overall objective of CARDIOPROOF is the development of tools and workflows for model building, customization and validation with clinical data. Once these models are capable of simulating a given patient’s physiology in its pre-treatment condition with high fidelity, it is assumed that they can also be employed to predict the acute impact of a planned intervention and perhaps also allow predictions of mid to long term outcomes. It is believed that such patient-specific models will augment existing diagnostic tools by allowing the prediction of post-treatment outcomes and thus improve clinical decision making by better informing patient selection and optimizing therapy delivery.
Cardiac MRI in particular already provides a large amount of patient-specific pathophysiological information that has been used to produce models and test treatment strategies.
Building a generic computational model of the heart
An electro-mechanical model of the heart consists of four major building blocks:
i) a geometric model describing a patient’s individual cardiac anatomy;
ii) a model representation of the electrical signalling, which regulates the pumping function;
iii) a biomechanical model which allows the computation of the contraction and relaxation of the heart; and
iv) a fluid flow model that computes blood flow in the cavity of the heart and the attached aorta.
Model equations describing the different physics have to be solved to compute the physiological quantities of interest. A set of such quantities is used to validate the model by assessing the match between computed signals and clinically recorded observations. A validated model can then be used to predict physiological alterations in response to planned interventions, but also to predict physiological signals that cannot be measured invivo, such as stresses.

Patient-specific customization
Building on such generic models,customization processes referred to as “parameterization” or “data assimilation” are needed so that model results match the specific clinical observations recorded for a patient. In particular, the anatomy of a patient has to be represented with high geometric fidelity. A fully automatic method for converting a tomographic image stack into a finite element model has been developed during the first year of CARDIOPROOF (see Fig. 1). Electrical activity of the heart recorded on a patient’s body surface in the form of an electrocardiogram (ECG) is used to parameterize the electrical model. The main differences in the electrical activation stem from inter-individual variations in the sites of earliest activation of the inner surface of the heart, the “endocardium”, which is excited by a network of fibres in the specialized conduction system. Further differences are due to variations in myocardial conduction velocities and the presence of non-conducting structures such as fibrosis or scar. The ECG recorded at the body surface is a global cumulative reflection of these processes in which the QRS depolarization signal reflects the activation process and the T-wave reflects electrical recovery. A methodology has been developed to find an electrical pattern for a givenpatient, which is consistent with the recorded ECG signals. The main advantage of this approach is that no invasive measurements are necessary for the parameterization electrical model components. The overall concept is outlined in Fig. 2.

The most demanding task is the parameterization of the mechanical model components.

Four model components have to be parametrized: i) a constitutive model describing the passive mechanical properties of ventricular tissue; ii) an active stress model, which drives contraction and relaxation of the ventricles; iii) a haemodynamic model of pressure and volumetric flow in the cardiovascular system during the ejection phase. All these components require patient-specific parameterization, which is based on pressurevolume (PV) data measured clinically prior to treatment.
The model components, their parameterization and the relative role they play over a full cardiac cycle are summarized in Fig. 3.

Computational Considerations
Such biophysically detailed simulations, if performed with the highest possible fidelity, are computationally expensive to the degree of severely impeding application in the clinic. This issue has been addressed in CARDIOPROOF in two complementary ways. First, the developed software framework allows us to swap model components and thus control the level of detail. Simpler computationally cheaper model components can then be used if computing resources are limited or time constraints are more severe. Alternatively,the underlying numerical machinery has been optimized for supercomputers and acceleration
devices, enabling sufficiently short simulation-analysis cycles for the envisioned clinical workflows.

In the final phase of the project,models will be built for a larger number of cases. Additional measurements, which are not standard in clinical routine, are being performed to facilitate a rigorous model validation. The impact of interventions, either the repair of an aortic valve or the stenting of an aortic coarctation,will be simulated and compared to additional post-treatment clinical data, thereby gauging the power of these models to predict clinical outcomes. If successful, computational models will become an indispensable complementary clinical modality over the next decade, contributing to significantly improved clinical outcomes for these types of interventions.

by Dr. Gernot Plank MEdical Univsersity of Graz

A clinical example – how modelling may improve clinical practice

A 23 year old female patient with a native bicuspid aortic valve (congenital heart disease) and with a di- lated ascending aorta. This is associated with aortic valve disease and the proposed treatment is an aortic valve replacement. The choice of a proper valve replacement is challenging.

Usability Engineering, Data Infrastructure, and Information System Design & Development

A major component within the Cardioproof project is the analysis of clinical requirements including data, content of use, clinical workflow, and data requirements gathered by other work packages. This data is then used with the goal of analysing and solving usability and workflow-related problems,which prevent the application of modelling and simulation methods in clinical practice.

Proof of model-based cardiovascular prediction in clinical settings


The rapid development of modelling and hardware tools promises an ability of a patient specific modelling of blood flow in a human blood circulation. Thanks to EU-funded projects, such as Virtual Human Project or e-Heart, the first modelling tools are available. We aim to prove the ability of modelling tools to work in clinical settings by a validation of modelling predictions for two groups of patients: patients with an aortic valve disease and patients with a narrowing of the aorta called coarctation that is a congenital heart disease.

Read more..

Virtual Stenting


Aortic coarctation is a narrowing of the aorta in the region of the transition between the aortic arch and the descending aorta where the fetal ductus arteriosus is joined. It occurs in about 7% of all congenital heart defects. The high afterload induced by the stenosis can lead to ventricular dysfunction and thus a major therapy goal is to remove the pressure gradient. According to the AHA Guidelines, balloon angioplasty with stenting is a minimally invasive recommended therapy for patients with a systolic pressure gradient of more than 20 mmHg (Feltes, et al. 2011). optimal stent placement is however a non-trivial task.


Physics developments and protocol optimisation at GOSH

Great Ormond Street Hospital (GOSH) is the biggest paedi- atric hospital in the UK and the Cardiac Unit is the big- gest paediatric congenital heart disease unit in Europe. Our centre for cardiovascular imaging at GOSH performed 1000 clinical scans and 500 research scans in 2013-2014 with a projected 50% increase in numbers for 2014-2015. In the MR (Magneto Resonance) Physics Development Group we augment the work of the Imaging Service at GOSH by significantly reducing scan times for routine imaging and increasing the numbers of children who can be scanned without anaesthesia. The Cardioproof protocol is extremely long with significant additional scanning required over and above routine clinical imaging. This may prolong scans times to over 1.5 hours, which is unacceptable to most patients in our population. Therefore, we have made a significant attempt to speed up the protocol by developing new accelerated sequences.

Read more..

CARDIOPROOF ‘s Bootstrapped Infrastructure

One of the central pillars of Cardioproof is the technical infrastructure that enables the safe hosting, transmission and analysis of the pa- tient data on which the project relies. Gnúbila, with consultation from clinical and technical partners, has put in place the first version of the infrastructure for the Cardioproof project. This infrastructure has been built on top on the ongoing FP7 project MD-Paedigree, as an extension to it, in order to make best use of time, effort and funding.

Read more..